Evaluation of rheumatologists’ knowledge of biosimilars
Abstract Introduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars. Methods Cross-sectional and descriptive study based on a questionnaire containing 17 it...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Advances in Rheumatology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42358-025-00465-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389052681256960 |
|---|---|
| author | Thayane Furtado Rolim Lima Lia Poti Gomes Cordeiro Kirla Wagner Poti Gomes Carlos Ewerton Maia Rodrigues |
| author_facet | Thayane Furtado Rolim Lima Lia Poti Gomes Cordeiro Kirla Wagner Poti Gomes Carlos Ewerton Maia Rodrigues |
| author_sort | Thayane Furtado Rolim Lima |
| collection | DOAJ |
| description | Abstract Introduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars. Methods Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars. Results Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars. Conclusion Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues. |
| format | Article |
| id | doaj-art-4a44f1120bcd4270b44da080f03c1ce7 |
| institution | Kabale University |
| issn | 2523-3106 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Advances in Rheumatology |
| spelling | doaj-art-4a44f1120bcd4270b44da080f03c1ce72025-08-20T03:42:04ZengBMCAdvances in Rheumatology2523-31062025-07-016511710.1186/s42358-025-00465-4Evaluation of rheumatologists’ knowledge of biosimilarsThayane Furtado Rolim Lima0Lia Poti Gomes Cordeiro1Kirla Wagner Poti Gomes2Carlos Ewerton Maia Rodrigues3Resident in Rheumatology, General Hospital of Fortaleza (HGF)Resident in Internal Medicine, Waldemar Alcântara General Hospital (HGWA)Health Sciences from University of Fortaleza (Unifor), General Hospital of Fortaleza (HGF)Graduate Program in Medical Sciences, Universidade de Fortaleza (Unifor)Abstract Introduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars. Methods Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars. Results Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars. Conclusion Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues.https://doi.org/10.1186/s42358-025-00465-4BiosimilarsBiosimilar drugsInterchangeabilityExtrapolation |
| spellingShingle | Thayane Furtado Rolim Lima Lia Poti Gomes Cordeiro Kirla Wagner Poti Gomes Carlos Ewerton Maia Rodrigues Evaluation of rheumatologists’ knowledge of biosimilars Advances in Rheumatology Biosimilars Biosimilar drugs Interchangeability Extrapolation |
| title | Evaluation of rheumatologists’ knowledge of biosimilars |
| title_full | Evaluation of rheumatologists’ knowledge of biosimilars |
| title_fullStr | Evaluation of rheumatologists’ knowledge of biosimilars |
| title_full_unstemmed | Evaluation of rheumatologists’ knowledge of biosimilars |
| title_short | Evaluation of rheumatologists’ knowledge of biosimilars |
| title_sort | evaluation of rheumatologists knowledge of biosimilars |
| topic | Biosimilars Biosimilar drugs Interchangeability Extrapolation |
| url | https://doi.org/10.1186/s42358-025-00465-4 |
| work_keys_str_mv | AT thayanefurtadorolimlima evaluationofrheumatologistsknowledgeofbiosimilars AT liapotigomescordeiro evaluationofrheumatologistsknowledgeofbiosimilars AT kirlawagnerpotigomes evaluationofrheumatologistsknowledgeofbiosimilars AT carlosewertonmaiarodrigues evaluationofrheumatologistsknowledgeofbiosimilars |